|
Volumn 15, Issue 5, 2010, Pages 488-491
|
Data submission standards and evidence requirements
a b c a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CARBOPLATIN;
CISPLATIN;
FLUOROURACIL;
FOLINIC ACID;
GEMCITABINE;
IRINOTECAN;
LAPATINIB;
MONOCLONAL ANTIBODY;
NEW DRUG;
PACLITAXEL;
PEMETREXED;
PLACEBO;
RECOMBINANT HUMAN VASCULOTROPIN MONOCLONAL ANTIBODY;
UNCLASSIFIED DRUG;
VASCULOTROPIN ANTIBODY;
ARTICLE;
BREAST CANCER;
CANCER RESEARCH;
CLINICAL RESEARCH;
COLORECTAL CANCER;
DATA COLLECTION METHOD;
DRUG RESEARCH;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
PATIENT PARTICIPATION;
PEER REVIEW;
PRIORITY JOURNAL;
SAMPLE SIZE;
STANDARD;
STREAMLINING DATA COLLECTION;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DATA COLLECTION;
FEMALE;
HUMANS;
MALE;
NEOPLASMS;
PRACTICE GUIDELINES AS TOPIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 77952646305
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2009-0260 Document Type: Article |
Times cited : (4)
|
References (4)
|